Zevacor Molecular is an affiliate of Zevacor Pharma, Inc (fka IBA Molecular North America, Inc.) and both are a subsidiary of Illinois Health and Science (IHS), a non-profit healthcare system that specializes in enhancing patient care through strategic investments in healthcare-related opportunities. The Zevacor family takes pride in helping fulfill IHS’s mission to enhance longevity and the quality of human life through improved patient care and outcomes.
Zevacor Pharma, Inc.
Zevacor Pharma, Inc. (formerly IBA Molecular North America, Inc.) is a leading developer, manufacturer, and distributor of radiopharmaceutical products and educational services used in nuclear medicine and molecular imaging in the United States. Zevacor has a unique product portfolio of tracers that are aimed at improving patient care through the better diagnosis and treatment of disease. Zevacor also provides investigative and custom radiolabeling services to pharmaceutical, biotech, and research institutions nationwide helping them develop the next generation of molecular imaging and therapeutic products.
Zevacor Molecular (Zevacor) is a U.S. healthcare firm that develops, manufactures and distributes PET and SPECT radiopharmaceuticals and associated educational services used in nuclear medicine. Established in 2012 and dedicated to providing medical isotopes to support the diagnosis and treatment of critical illnesses, Zevacor is finalizing the construction of a new 70 MeV cyclotron and multiple synthesis and processing units for production and distribution of a broad range of clinical and research radioisotopes at its Noblesville, IN headquarters.
Zevacor Pharma, Inc. is an Equal Opportunity / Affirmative Action employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability, protected veteran status, or other characteristic protected by law.